As an excipient, the formulation contains 4 grams of sorbitol.

The underlying disease may not reflect the risk of thromboembolic event (DVT, Pulmonary embolisms, NSTEMI and stroke).

As soon as possible, you should resume treatment with dabigatran. After 24 hours, it can be restarted.

Because these patients have an underlying condition that predisposes to thromboembolic episodes, the risk of them developing thromboembolic complications increases when dabigatran is stopped.

If a hypersensitivity reaction occurs, the treatment should be stopped immediately.

Patients with hypersensitivity reactions to any component of the drug or the drug should weigh the benefits and risks of therapy.

Not all hypersensitivity reactions have been evaluated.

Allergy reactions to idarucizumab and any component of this formulation.

Uncommon Side effects of Idarucizumab (Praxbind):Ĭontraindications to Idarucizumab (Praxbind) : Side Effects of Idarucizumab (Praxbind) : In the manufacturer's labeling, adjustments in the dose has not been provided/ recommended. Idarucizumab (Praxbind) Dose in Liver disease: Furthermore, the reversal effect of idarucizumab is not affected by renal dysfunction. Idarucizumab (Praxbind) Dose in Kidney Disease:Īdjustment in the dose is not necessary in patients with renal disease.

It is recommended that you use it with caution if you are breastfeeding.It is unknown if the drug will be excreted into breastmilk.It has not yet been tested in pregnant women or animals.The safety and efficacy of the drug in children have not been established. Patients who develop intracranial or refractory bleeding secondary to dabigatran, hemodialysis, or re-dosing may be considered if refractory bleeding occurs after the initial dose of idarucizumab.An additional two doses of 2.5 gms (total 5 gms) may be administered if the coagulation profile is abnormal or the patient is actively bleeding, or another surgical procedure is required.5 gms administered intravenously as two separate doses of 2.5 gms each no more than 15 minutes apart.Idarucizumab (Praxbind) Dose in Adults: Idarucizumab (Praxbind) Dose in the treatment of reversal of dabigatran: It is indicated to reverse the anticoagulant effects of dabigatran in patients with uncontrolled or life-threatening bleeding, and in patients undergoing an emergency procedure.

Idarucizumab (Praxbind) is a humanized monoclonal antibody that is used to reverse the effects of dabigatran. Vaccines & immunoglobulins Vitamins Gout treatment Featured Video Consultation

Praxbind dose